• Record sales contracts of $89.0 million, up 116% from FY25
• Group revenue of $60.9 million, up 15% from FY25
• EBITDA of $18.3 million at 30% margin
• Profit after tax of $11.9 million, earnings per share of $0.0696
• Fully franked annual dividend of A$0.04 per ordinary share declared

Cogstate Ltd, a science-led clinical trial endpoint company, released its FY26 financial results, highlighting record sales contracts of $89.0 million, a 116% increase from FY25. Group revenue rose 15% to $60.9 million, driven by sustained demand across a diversified CNS clinical trials portfolio. The company achieved EBITDA of $18.3 million at a 30% margin, with EBIT of $15.2 million at a 25% margin. Profit before tax was $16.1 million, and profit after tax was $11.9 million, with earnings per share of $0.0696. Cogstate ended FY26 with a cash balance of $34.8 million and no debt, enabling continued investment in technology and AI-enabled scale. The company also declared a fully franked annual dividend of A$0.04 per ordinary share.

FY27 revenue expected to be $118.5 million, up 32% from FY25

Cogstate expects to maintain FY26 annual EBITDA margins in FY27, despite increased investments and operating platform enhancements, driven by record contracted future revenue.